Form 4: Acrivon Therapeutics Director Acquires RSUs

Acrivon Therapeutics Director Sharon Shacham acquired 9,366 restricted stock units (RSUs) on May 18, 2026, which are set to vest on May 18, 2027.

Summary

• Sharon Shacham, a Director at Acrivon Therapeutics, Inc., acquired 9,366 restricted stock units (RSUs) on May 18, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Common Stock per unit.
• The RSUs are scheduled to vest in full on May 18, 2027, provided that the Reporting Person remains in continuous service with the company through that date.
• The acquisition was made at a price of $0, indicating it was likely a grant or award rather than a purchase.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider equity grant rather than a significant financial event or performance indicator.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The grant of RSUs is a common form of executive compensation tied to continued service and company performance.
• The vesting schedule aligns the director's incentives with long-term value creation.

Risks

• The RSUs are subject to forfeiture if the Reporting Person's continuous service is not maintained through the vesting date.
• The value of the RSUs is tied to the future performance and stock price of Acrivon Therapeutics, which carries inherent market risk.

Future Outlook

The RSUs will vest on May 18, 2027, contingent upon the Reporting Person's continued employment.

Industry Context

StockSavvy.ai notes that insider grants of equity, such as these RSUs, are a standard practice in the biotechnology and pharmaceutical sectors to attract and retain key talent and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition by a director can be seen as a positive signal of commitment, but the immediate impact on share price is minimal as it's an equity grant, not a purchase on the open market.
• Employees: The RSU grant structure is typical for management and directors, reinforcing performance-based compensation models.
• Management: Aligns director's incentives with long-term company performance and shareholder value.

Next Steps

• Continuous service by Sharon Shacham through May 18, 2027, for RSUs to vest.
• Potential future reporting of RSU vesting and subsequent share ownership.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSUs, Director Compensation, Equity Award, Vesting Schedule